Acadia Pharmaceuticals (ACAD)

Company Description

ACADIA Pharmaceuticals (ACAD) focuses on the development and commercialization of small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders. Its lead drug candidate is NUPLAZID, which has delivered positive data in Phase III pivotal trials with a pristine safety profile for the treatment of Parkinson’s disease psychosis, an unmet medical need.   The potential blockbuster is also in Phase II development for Alzheimer’s disease psychosis and is currently planning a Phase II trial for the treatment of schizophrenia. ACAD also has clinical-stage programs for chronic pain and glaucoma in collaboration with Allergan, Inc.

 

COMPANY ADDRESS
3611 Valley Centre Drive; Suite 300
San Diego, CA 92130
United States

COMPANY PHONE
(858) 558-2871

COMPANY WEBSITE


Get BioInvest's perspective on Acadia's CEO

Latest Company News

Analyst Target Update & Review on ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Rockville Register - 13 hours ago ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) shares traded -0.80% during the most recent session. Wall Street analysts covering the stock are projecting that the stock will reach $43.55 within the next 52-weeks. ACADIA Pharmaceuticals Inc. (ACAD) Moves Higher on Volume Spike for April 25 - Equities.com Hot On The Charts: Otonomy, Inc. (OTIC), ACADIA Pharmaceuticals Inc. (ACAD) - Post Analyst [...]
Thu, Apr 27, 2017 4:52:00 PM, Continue reading at the source
Market Update: Looking at the Levels for ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) BVN - 19 hours ago ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) has a current Value Composite Score of 91. Using a scale from 0 to 100, a lower score would represent an undervalued company and a higher score would indicate an expensive or overvalued company. [...]
Thu, Apr 27, 2017 10:30:00 AM, Continue reading at the source
ACADIA Pharmaceuticals Inc. (ACAD) Isn't Shy About Revealing Its Soul In The ... NY Stock News - Apr 26, 2017 ACADIA Pharmaceuticals Inc. (ACAD) has been having a set of eventful trading activity and it is clear from an examination of the charts that traders are now fully aware of the company's key metrics. [...]
Wed, Apr 26, 2017 6:11:00 PM, Continue reading at the source
Quidel (QDEL) At $23.50 Forms Bottom; Acadia Pharmaceuticals (ACAD) Sellers ... HuronReport - Apr 25, 2017 The SI to Acadia Pharmaceuticals Incorporated's float is 21.71%. The stock increased 4.69% or $1.51 during the last trading session, reaching $33.72. [...]
Tue, Apr 25, 2017 10:30:00 AM, Continue reading at the source
Acadia Pharmaceuticals Becomes Oversold (ACAD) Nasdaq - Apr 5, 2017 In trading on Wednesday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) entered into oversold territory, hitting an RSI reading of 27.9, after changing hands as low as $32.48 per share. [...]
Wed, Apr 05, 2017 8:48:00 PM, Continue reading at the source
ACADIA Pharmaceuticals Announces Appointment of Michael J. Yang as Executive ... Yahoo Finance - Mar 30, 2017 ACADIA Pharmaceuticals Inc. (ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced Michael J. Yang ... [...]
Thu, Mar 30, 2017 12:00:00 PM, Continue reading at the source
ACADIA Pharmaceuticals to Present at Needham & Company's 16th Annual ... Yahoo Finance - Mar 29, 2017 ACADIA Pharmaceuticals Inc. (ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at ... Revenue Approximations Analysis: India Globalization Capital, Inc. (IGC ... - StockNewsJournal ACADIA Pharmaceuticals Inc. (ACAD) Rating Increased to Hold at Zacks ... - Sports Perspectives [...]
Wed, Mar 29, 2017 12:56:00 PM, Continue reading at the source
ACADIA Pharma Looks Like A Take-Out Target Seeking Alpha - Feb 27, 2017 But one company in particular has this San Diegan very interested. The company I'm talking about is ACADIA Pharmaceuticals (NASDAQ:ACAD), and in a field of speculative, pre-FDA-approval pharma companies, ACADIA has potential few others possess. [...]
Mon, Feb 27, 2017 7:41:00 PM, Continue reading at the source
Why Acadia Pharmaceuticals Inc. Stock Slipped 19% in 2016 Motley Fool - Jan 13, 2017 Shares of Acadia Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company focused on treating central nervous system disorders, fell 19.1% last year, according to data from S&P Global Market Intelligence. Cowen's Take On ACADIA Pharmaceuticals Inc. (ACAD) Following Presentation At ... - Smarter Analyst [...]
Fri, Jan 13, 2017 1:24:00 PM, Continue reading at the source
Why ACADIA Pharmaceuticals Inc. Is Soaring Today Motley Fool - Dec 20, 2016 Acadia released top-line results from its Phase II -019 Study today. This trial was designed to test its drug Nuplazid (pimavanserin) as a hopeful treatment for Alzheimer's disease psychosis. [...]
Tue, Dec 20, 2016 7:43:00 PM, Continue reading at the source